Shots:
The third quarter of 2024 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The highlight of the quarter was Eli Lilly's acquisition of Morphic Holdings for ~$3.2B
This quarter also showcased multiple clinical trial results including Roche's P-I Study Data of CT-996 to treat Obesity
Our…
Shots:
Known for delivering the same therapeutic benefits as its brand-name counterpart, it won't be an exaggeration to refer to generic drugs as modern-day advocates for health equity
In 2022, the global market size of generic drugs was valued at $411.99B and is envisioned to reach $613.34B by 2030 with a CAGR of 5.10%. Sandoz…
Shots:
The US FDA has granted approval to the company’s Leqselvi (8mg) tablets for treating severe alopecia areata adults
Approval was supported by two P-III (THRIVE-AA1 & THRIVE-AA2) studies that assessed the scalp hair regrowth using the SALT score with Leqselvi (8mg or 12mg, BID) vs PBO in adults (n=1223; 18-65yrs.) with severe alopecia areata…
Shots:
Third quarter of 2023 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. Starting with the latest acquisitions, Biogen acquired Reata Pharmaceuticals for ~$7.3B and Danaher acquired Abcam for ~$5.7B
The third quarter of the year also showcases multiple clinical trial results which include Janssen reported P-IIb…
Shots:
Generic medicines are the backbone of the healthcare system and are identical to the innovator medicine in strength- effect- dosage form- and route of administration. These are allowed for sale after the patent expiry of the original drugs
Our team at PharmaShots has compiled a list of the top 20 generic companies based on…

